E2F1 downregulation by arsenic trioxide in lung adenocarcinoma

Lam,Sze-Kwan; Li,Yuan-Yuan; Zheng,Chun-Yan; Leung,Leanne  Lee; Ho,James   Chung-Man

doi:10.3892/ijo.2014.2609

E2F1 downregulation by arsenic trioxide in lung adenocarcinoma

Authors:
- Sze-Kwan Lam
- Yuan-Yuan Li
- Chun-Yan Zheng
- Leanne Lee Leung
- James Chung-Man Ho
View Affiliations

Affiliations: Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, P.R. China
Published online on: August 19, 2014 https://doi.org/10.3892/ijo.2014.2609
Pages: 2033-2043

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common cancers worldwide. Arsenic trioxide (ATO) has been approved by the US Food and Drug Administration for the treatment of acute promyelocytic leukemia. Nonetheless preliminary data have suggested potential activity of ATO in solid tumors including lung cancer. This study aimed to examine the underlying mechanisms of ATO in the treatment of lung adenocarcinoma. Using a panel of 7 lung adenocarcinoma cell lines, the effects of ATO treatment on cell viability, expression of E2F1 and its downstream targets, phosphatidylserine externalization, mitochondrial membrane depolarization and alteration of apoptotic/anti-apoptotic factors were studied. Tumor growth inhibition in vivo was investigated using a nude mouse xenograft model. ATO decreased cell viability with clinically achievable concentrations (8 µM) in all cell lines investigated. This was accompanied by reduced expression of E2F1, cyclin A2, skp2, c-myc, thymidine kinase and ribonucleotide reductase M1, while p-c-Jun was upregulated. Cell viability was significantly decreased with E2F1 knockdown. Treatment with ATO resulted in phosphatidylserine externalization in H23 cells and mitochondrial membrane depolarization in all cell lines, associated with truncation of Bid, downregulation of Bcl-2, upregulation of Bax and Bak, caspase-9 and -3 activation and PARP cleavage. Using the H358 xenograft model, the tumor growth was suppressed in the ATO treatment group during 8 days of treatment, associated with downregulation of E2F1 and upregulation of truncated Bid and cleaved caspase-3. In conclusion, ATO has potent in vitro and in vivo activity in lung adenocarcinoma, partially mediated through E2F1 downregulation and apoptosis.

View Figures

View References

1	Yano T, Haro A, Shikada Y, Maruyama R and Maehara Y: Non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features. Int J Clin Oncol. 16:287–293. 2011.
2	Favaretto AG, Pasello G and Magro C: Second and third line treatment in advanced non-small cell lung cancer. Discov Med. 8:204–209. 2009.PubMed/NCBI
3	Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar
4	Suda K, Onozato R, Yatabe Y and Mitsudomi T: EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol. 4:1–4. 2009. View Article : Google Scholar : PubMed/NCBI
5	Au WY, Kumana CR, Kou M, et al: Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 102:407–408. 2003. View Article : Google Scholar : PubMed/NCBI
6	Chien CW, Yao JH, Chang SY, Lee PC and Lee TC: Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. Toxicol Appl Pharmacol. 257:59–66. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ghaffari SH, Momeny M, Bashash D, Mirzaei R, Ghavamzadeh A and Alimoghaddam K: Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkbeta-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology. 17:198–206. 2012. View Article : Google Scholar : PubMed/NCBI
8	Han YH, Kim SZ, Kim SH and Park WH: Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 270:40–55. 2008. View Article : Google Scholar : PubMed/NCBI
9	Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL and Ho JC: Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma. Int J Oncol. 44:2093–2102. 2014.PubMed/NCBI
10	Slee EA and Lu X: Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis. Sci Rep. 3:31052013.PubMed/NCBI
11	Tsantoulis PK and Gorgoulis VG: Involvement of E2F transcription factor family in cancer. Eur J Cancer. 41:2403–2414. 2005. View Article : Google Scholar : PubMed/NCBI
12	Huang CL, Liu D, Nakano J, et al: E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res. 13:6938–6946. 2007. View Article : Google Scholar : PubMed/NCBI
13	Gorgoulis VG, Zacharatos P, Mariatos G, et al: Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol. 198:142–156. 2002. View Article : Google Scholar : PubMed/NCBI
14	Liontos M, Niforou K, Velimezi G, et al: Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol. 175:376–391. 2009. View Article : Google Scholar : PubMed/NCBI
15	Li YY, Lam SK, Mak JC, Zheng CY and Ho JC: Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer. 81:354–361. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kousparou CA, Yiacoumi E, Deonarain MP and Epenetos AA: Generation of a selectively cytotoxic fusion protein against p53 mutated cancers. BMC Cancer. 12:3382012. View Article : Google Scholar
17	Yamauchi KIY, Ogata K, Hara S, Tamura K, Suzumiya J, Ishitsuka K and Ono N: Pharmacokinetics of arsenic trioxide in Japanese patients with acute promyelocytic leukemia and adult T-cell leukemia lymphoma. Jpn J Pharmaceut Health Care Sci. 30:492–496. 2004. View Article : Google Scholar
18	Chen GQ, Shi XG, Tang W, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As₂O₃ exerts dose-dependent dual effects on APL cells. Blood. 89:3345–3353. 1997.PubMed/NCBI
19	Bustamante J, Nutt L, Orrenius S and Gogvadze V: Arsenic stimulates release of cytochrome c from isolated mitochondria via induction of mitochondrial permeability transition. Toxicol Appl Pharmacol. 207:110–116. 2005.PubMed/NCBI
20	Momeny M, Zakidizaji M, Ghasemi R, et al: Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 27:833–842. 2010.
21	Meng R, Zhou J, Sui M, Li Z, Feng G and Yang B: Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line. Sci China Life Sci. 53:87–93. 2010. View Article : Google Scholar : PubMed/NCBI
22	Baek JH, Moon CH, Cha SJ, et al: Arsenic trioxide induces depolymerization of microtubules in an acute promyelocytic leukemia cell line. Korean J Hematol. 47:105–112. 2012. View Article : Google Scholar : PubMed/NCBI
23	Worku D, Jouhra F, Jiang GW, Patani N, Newbold RF and Mokbel K: Evidence of a tumour suppressive function of E2F1 gene in human breast cancer. Anticancer Res. 28:2135–2139. 2008.PubMed/NCBI
24	Xu F, You X, Liu F, et al: The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells. Cancer Lett. 333:124–132. 2013. View Article : Google Scholar : PubMed/NCBI
25	Onda M, Nagai H, Yoshida A, et al: Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers. J Hum Genet. 49:312–318. 2004. View Article : Google Scholar : PubMed/NCBI
26	Farra R, Dapas B, Pozzato G, et al: Effects of E2F1-cyclin E1–E2 circuit down regulation in hepatocellular carcinoma cells. Dig Liver Dis. 43:1006–1014. 2011.
27	Yamazaki K, Yajima T, Nagao T, et al: Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol Res Pract. 199:23–28. 2003. View Article : Google Scholar : PubMed/NCBI
28	Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326. 2002. View Article : Google Scholar : PubMed/NCBI
29	Hilbe W, Dirnhofer S, Greil R and Woll E: Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev. 13:425–436. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ceppi P, Rapa I, Lo Iacono M, et al: Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. Int J Cancer. 130:1777–1786. 2012. View Article : Google Scholar : PubMed/NCBI
31	Hung WC, Tseng WL, Shiea J and Chang HC: Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett. 288:156–161. 2010. View Article : Google Scholar : PubMed/NCBI
32	Huang ZH, Tian XS, Li R, et al: Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med. 3:331–335. 2012.
33	Wang L, Meng L, Wang XW, Ma GY and Chen JH: Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 35:1899–1906. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ryu BJ, Hwang MK, Park M, Lee K and Kim SH: Thiourea compound AW00178 sensitizes human H1299 lung carcinoma cells to TRAIL-mediated apoptosis. Bioorg Med Chem Lett. 22:3862–3865. 2012. View Article : Google Scholar : PubMed/NCBI
35	Filomeni G, Turella P, Dupuis ML, et al: 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther. 7:371–379. 2008. View Article : Google Scholar
36	Walker T, Nolte A, Steger V, et al: Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection. Eur J Cardiothorac Surg. 43:624–633. 2013.
37	Hu T, Shi J, Jiao X, Zhou J and Yin X: Measurement of Annexin V uptake and lactadherin labeling for the quantification of apoptosis in adherent Tca8113 and ACC-2 cells. Braz J Med Biol Res. 41:750–757. 2008. View Article : Google Scholar : PubMed/NCBI
38	Korper S, Nolte F, Thiel E, Schrezenmeier H and Rojewski MT: The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines. Br J Haematol. 124:186–189. 2004. View Article : Google Scholar : PubMed/NCBI
39	Shen ZY, Shen J, Cai WJ, Hong C and Zheng MH: The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med. 5:155–158. 2000.PubMed/NCBI
40	Wang Y, Xu Y, Wang H, et al: Arsenic induces mitochondria-dependent apoptosis by reactive oxygen species generation rather than glutathione depletion in Chang human hepatocytes. Arch Toxicol. 83:899–908. 2009. View Article : Google Scholar
41	Xu Y, Wang H, Wang Y, Zheng Y and Sun G: Effects of folate on arsenic toxicity in Chang human hepatocytes: involvement of folate antioxidant properties. Toxicol Lett. 195:44–50. 2010. View Article : Google Scholar : PubMed/NCBI
42	Jin HO, Seo SK, Woo SH, et al: A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung Cancer. 61:317–327. 2008. View Article : Google Scholar
43	Jin HO, Yoon SI, Seo SK, et al: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol. 72:1228–1236. 2006. View Article : Google Scholar : PubMed/NCBI
44	Qin DB, Chen JP and Wang SQ: Mechanism of apoptosis of NB4 cells induced by arsenic trioxide and cyclooxygenase-2 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 19:648–651. 2011.(In Chinese).
45	Su Y, Wang X, Xu W, et al: Arsenic trioxide increases the sensitivity of 786–0 renal carcinoma cells to radiotherapy. Cancer Invest. 30:114–118. 2012.PubMed/NCBI
46	Tung JN, Cheng YW, Hsu CH, et al: Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carcinoma. Ann Surg Oncol. 18:1492–1500. 2011. View Article : Google Scholar
47	Li HC, Wang CX, Huang C, et al: Effect and mechanism of arsenic trioxide on chemosensitivity of human lung adenocarcinoma cells. Zhonghua Jie He He Hu Xi Za Zhi. 26:689–692. 2003.(In Chinese).
48	Shi Y, Liu Y, Huo J and Gao G: Arsenic trioxide induced apoptosis and expression of p53 and bcl-2 genes in human small cell lung cancer cells. Zhonghua Jie He He Hu Xi Za Zhi. 25:665–666. 2002.PubMed/NCBI
49	Pettersson HM, Pietras A, Munksgaard Persson M, et al: Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther. 8:160–170. 2009. View Article : Google Scholar : PubMed/NCBI
50	Yuan Z, Wang F, Zhao Z, et al: BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One. 6:e205862011. View Article : Google Scholar : PubMed/NCBI
51	Potin S, Bertoglio J and Breard J: Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells. FEBS Lett. 581:118–124. 2007. View Article : Google Scholar : PubMed/NCBI
52	Walker AM, Stevens JJ, Ndebele K and Tchounwou PB: Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells. Int J Environ Res Public Health. 7:1996–2007. 2010. View Article : Google Scholar
53	Bairey O, Vanichkin A and Shpilberg O: Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol. 32:e77–85. 2010. View Article : Google Scholar : PubMed/NCBI
54	Cheng Y, Chang LW and Tsou TC: Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol. 80:310–318. 2006. View Article : Google Scholar
55	Luo M, Lu Z, Sun H, et al: Nuclear entry of active caspase-3 is facilitated by its p3-recognition-based specific cleavage activity. Cell Res. 20:211–222. 2010. View Article : Google Scholar : PubMed/NCBI